博瑞醫藥(688166.SH):獲得“磷酸奧司他韋膠囊”的藥品註冊證書
格隆匯8月2日丨博瑞醫藥(688166.SH)公佈,近日,公司全資子公司博瑞製藥(蘇州)有限公司(“博瑞製藥”)收到國家藥品監督管理局核准簽發的“磷酸奧司他韋膠囊”《藥品註冊證書》。
該藥品用於成人和1歲及1歲以上兒童的甲型和乙型流感治療(磷酸奧司他韋能夠有效治療甲型和乙型流感,但是乙型流感的臨牀應用數據尚不多)。用於成人和13歲及13歲以上青少年的甲型和乙型流感的預防。
磷酸奧司他韋已成為世界衞生組織(WHO)推薦的基本藥物,被美國和歐洲疾病預防控制中心推薦為主要的抗流感病毒藥物,並進入中國 2018 版基藥目錄,同時也是《流行性感冒診療方案(2018 年版修訂版)》明確的抗流感病毒藥物,臨牀地位顯著。該藥物原研廠家為羅氏製藥有限公司,奧司他韋化合物專利在中國已於2016年2月26日到期,磷酸奧司他韋化合物專利在中國已於2017年8月22日到期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.